PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.
Naga P ChalasaniEduardo Vilar-GomezStephen CaldwellKatherine P YatesAnna Mae DiehlBrent A Neuschwander-TetriSrinivasan DasarathyKris V KowdleyNorah A TerraultLaura A WilsonJames TonasciaArun J SanyalPublished in: Hepatology (Baltimore, Md.) (2024)
The deleterious effects of PNPLA3 rs738409 on the risk of MALO are significantly worsened by AF, age, type 2 diabetes mellitus, and sex.